Overview

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Status:
Completed
Trial end date:
2018-01-27
Target enrollment:
Participant gender:
Summary
This is a phase 1 open-label 4-part study to evaluate the effect of food, cytochrome P450 inhibition and induction on the pharmacokinetics of CC 122 in healthy adult subjects. Approximately 81 subjects will be enrolled. There will be approximately 24 subjects in Part 1 and approximately 19 subjects in Parts 2, 3, and 4, respectively. Subjects may participate in 1 part only.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Treatments:
Fluvoxamine
Hydroxyitraconazole
Itraconazole
Rifampin